Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
2.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
3.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Pharmacoeconomics. 2012 Aug 1;30(8):e1-15. doi: 10.2165/11632920-000000000-00000.

4.

Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.

Childress AC, Berry SA.

Drugs. 2012 Feb 12;72(3):309-25. doi: 10.2165/11599580-000000000-00000. Review.

PMID:
22316347
5.

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.

Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Appl Health Econ Health Policy. 2012 Nov 1;10(6):381-95. doi: 10.2165/11641870-000000000-00000. Erratum in: Appl Health Econ Health Policy. 2013 Jun;11(3):309. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
23113551
6.

Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Childress AC.

Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. Epub 2012 May 18. Review.

PMID:
22610723
7.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
8.
9.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
10.

Guanfacine extended-release: in attention deficit hyperactivity disorder.

Muir VJ, Perry CM.

Drugs. 2010 Sep 10;70(13):1693-702. doi: 10.2165/11205940-000000000-00000. Review.

PMID:
20731476
11.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
12.

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Wigal SB.

CNS Drugs. 2009;23 Suppl 1:21-31. doi: 10.2165/00023210-200923000-00004. Review.

PMID:
19621975
13.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Wigal SB, Chae S, Patel A, Steinberg-Epstein R.

Semin Pediatr Neurol. 2010 Dec;17(4):230-6. doi: 10.1016/j.spen.2010.10.005. Review.

PMID:
21183129
14.

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychiatry. 2006;67 Suppl 8:32-8. Review.

15.

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.

Biederman J, Spencer T, Wilens T.

Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97. Epub 2004 Jan 21. Review.

PMID:
14733627
16.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
17.

Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.

Kaplan G, Newcorn JH.

Pediatr Clin North Am. 2011 Feb;58(1):99-120, xi. doi: 10.1016/j.pcl.2010.10.009. Review.

PMID:
21281851
18.

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.

Faraone SV, Glatt SJ.

J Clin Psychiatry. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.

PMID:
20051220
19.

Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).

Sallee FR, Eaton K.

Expert Opin Pharmacother. 2010 Oct;11(15):2549-56. doi: 10.1517/14656566.2010.517523. Review.

PMID:
20831361
20.

The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.

Himpel S, Banaschewski T, Heise CA, Rothenberger A.

Expert Opin Drug Saf. 2005 Mar;4(2):311-21. Review.

PMID:
15794722
Items per page

Supplemental Content

Write to the Help Desk